Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on December 31, 2019, 01:10:13 pm

Title: Another Blow to Merck in $2.5 Billion Hep C Patent Suit Against Gilead
Post by: Hep Editors on December 31, 2019, 01:10:13 pm
Merck lost out in yet another round in its attempt to secure $2.54 billion in damages in a patent dispute with Gilead Sciences over the hepatitis C virus (HCV) blockbuster drugs Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), Reuters reports. A U.S. appeals court upheld a ruling by a federal judge in Delaware that found that the Merck patent in question was invalid.

In 2016, a jury found that Gilead’s Sovaldi and Harvoni infringed upon the patent that Merck secured when it acquired Idenix Pharmaceuticals. The $2.54 billion that the jury concluded Gilead should pay Merck in damages set a U.S. patent case record.